Shots:

• The P-III (PaTHway) trial evaluates TransCon PTH vs PBO in a ratio (3:1) in 82 adults patients with chronic HP
• The therapy showed an improvement on the primary composite EPs & 2EPs, 78.7% vs 4.8% achieved serum calcium levels in the normal range & independence from therapeutic levels of conventional therapy, reduction in patient-reported disease impact along with physical & cognitive symptoms, was well tolerated with no discontinuations related to study drug, TEAEs (82% vs 100%). The top-line results are expected in Q3’22
• The company plans to submit an NDA to the US FDA for TransCon PTH in Q3’22 & MAA to EMA in Q4’22 & is also planning to initiate a clinical trial in pediatric HP in Q4’22

Ref: Globe Newswire | Image: Ascendis Pharma